Kinomica

Macclesfield, United Kingdom Founded: 2017 • Age: 9 yrs
Bioinformatics platform for precision medicine development is offered.
Annual revenue - Latest available
Total funding $5.2M 2 rounds
Employees 13 Tracked headcount
Investors 5 Known backers
Products 1 Services tracked
Competitors 10 Brand Intelligence

About Kinomica

Kinomica is a company based in Macclesfield (United Kingdom) founded in 2017 by John Gribben, Pedro Cutillas, and David Britton. Kinomica has raised $5.16 million across 2 funding rounds from investors including Alderley Park, BioCity and BGF. The company has 13 employees as of June 30, 2021. Kinomica offers products and services including KScan®. Kinomica operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.

  • Headquarter Macclesfield, United Kingdom
  • Employees 13 as on 30 Jun, 2021
  • Founders John Gribben, Pedro Cutillas, David Britton
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Kinomica Limited
  • Date of Incorporation 01 Oct, 2016
  • Jurisdiction MACCLESFIELD, CHESHIRE, ENGLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $5.16 M (USD)

    in 2 rounds

  • Latest Funding Round
    $5.16 M (USD), Series A

    Dec 14, 2020

  • Investors
  • Employee Count
    13

    as on Jun 30, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Kinomica

Kinomica offers a comprehensive portfolio of products and services, including KScan®.

Product name locked
Category locked
Primary

Analyzes protein phosphorylation for cancer treatment selection and precision medicine.

People of Kinomica

Headcount 1-10
Employee Profiles 4
Employee Profiles
People
Andrew J. Thompson
Program Director
People
Arran Dokal
Chief Technology Officer
People
Weronika Borek, PhD
Bioinformatics Technical Lead

Unlock access to complete

Teams

Funding Insights of Kinomica

Kinomica has successfully raised a total of $5.16M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5.16 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Kinomica

Kinomica has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Alderley Park, BioCity and BGF.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
Locked Locked Locked
Early-stage deeptech businesses are supported through venture capital investments.
Locked Locked Locked
Life Science focused startup accelerator and incubator
Locked Locked Locked
Premium access

Investor details for Kinomica

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Kinomica

Investments
Premium access

Investment portfolio details for Kinomica

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Kinomica

Premium access

Detailed financials for Kinomica

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Kinomica Comparisons

Kinomica Primary company
Description
Bioinformatics platform for precision medicine development i...
Location
Macclesfield, United Kingdom
Founded Year
2017
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
13
As of 2021
Premium access

Peer comparison for Kinomica

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Kinomica

Kinomica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
RNA interference-based therapeutics are developed for multiple disorders.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Locked Locked Locked
Therapeutics for rare and ultra-rare metabolic diseases are developed.
Premium access

Detailed competitors of Kinomica

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Kinomica

Premium access

Complete news archive for Kinomica

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kinomica

Kinomica was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Kinomica is headquartered in Macclesfield, United Kingdom. It is registered at Macclesfield, Cheshire, United Kingdom.

Jane Theaker is the current CEO of Kinomica.

Kinomica is a funded company, having raised a total of $5.16M across 2 funding rounds to date.

As of Jun 30, 2021, the latest employee count at Kinomica is 13.

Kinomica was founded in 2017 and is headquartered in Macclesfield, United Kingdom. A bioinformatics platform is provided by the company within the precision medicine sector. Proprietary bioinformatics and LC-MSMS phospho-proteomics are utilized to examine cellular signaling activities and biochemical network changes. Applications encompass the study of disease mechanisms, identification of drug targets and biomarkers, assessment of drug efficacy, and determination of therapy responders.

Kinomica's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Kinomica offers KScan®.

Kinomica has 5 investors. Key investors include Alderley Park, BioCity, BGF, Longwall Ventures, and Puffin Point.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available